Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: WWS who wrote (1879)	8/20/1999 6:45:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 2205

Bill, The problem with xenotransplants is that usually the patient must be on an immunosurpressant drug for the rest of their life or run the risk of transplant rejection. Also, those drugs on the market for transplant rejection must be approved for animal-to-human use. Once one factors in the lifetime cost of immunosurpressant drugs, they are very costly, it isn't a very attractive alternative if there is a bioengineered human organ available where the rejection risk is eliminated. Finally, the Physicians Committee for Responsible Medicine (PCRM} issued a statement for the government to outlaw animal-to-human transplants. I am not familiar with this group and for all that I know may be a splinter group of the flat Earth society but it does illustrate the emotions involved in this issue. They are concerned that transplanted pathogens capable of causing catastropic illness in humans.